Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability and Efficacy of Adjunctive Treatment With Topically Applied MBN-101 in Patients With Moderate to Severe Diabetic Foot Infection (DFI)

NCT02723539 is registered in ClinicalTrials.gov with Microbion Corporation as lead sponsor.

NCT NCT02723539
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02723539 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability and Efficacy of Adjunctive Treatment With Topically Applied MBN-101 in Patients With Moderate to Severe Diabetic Foot Infection (DFI)
Lead sponsor
Microbion Corporation
Phase
Phase 1
Overall status
Completed
Start date
March 6, 2017
Completion date
July 26, 2019
Enrollment
52 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic foot infection